People · Operator
Named in public records as an officer, director or promoter · active 2016–2016 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Neurotrope, Inc. | — | Biotechnology | Series B | $40.9M | $972.6M | 2016 |
Kenneth Gorelick at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kenneth Gorelick on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Joshua Silverman | 1 | 8 |
| Robert Weinstein | 1 | 6 |
| Bruce Bernstein | 1 | 5 |
| John Abeles | 1 | 4 |
| Paul E. Freiman | 1 | 2 |
| James New | 1 | 2 |
| Ralph Bean | 1 | 2 |
| William Singer | 1 | 2 |
| Shana Phares | 1 | 1 |
| Dan Alkon | 1 | 1 |
| Susanne Wilke | 1 | 1 |
| Jay M. Haft | 1 | 1 |
| Robert S. Weinstein | 1 | 1 |
| Larry D. Altstiel, MD | 1 | 1 |
| William E. Singer | 1 | 1 |
| Charles S. Ramat | 1 | 1 |
| James E. Gottlieb | 1 | 1 |
| James Gottlieb | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.